Annual report pursuant to Section 13 and 15(d)

In-Process Research and Development

v3.20.4
In-Process Research and Development
12 Months Ended
Dec. 31, 2020
Research And Development [Abstract]  
In-Process Research and Development

NOTE 15 – IN-PROCESS RESEARCH AND DEVELOPMENT

In December 2020, the Company completed the sale of Evofosfamide which was previously classified as In-process research and development - held for sale. In connection with sale, the Company recorded a loss on assets held for sale of $2.0 million which is the difference between the carrying value and the consideration received.